FRANKFURT: Coronavirus jab maker BioNTech said on Monday it would build a southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of mRNA-based vaccines per year. It is now supplying more than 90 countries worldwide and is expecting to ramp up its production to up to three billion doses by the end of the year from 2.5 billion doses expected previously. The pace will further accelerate to more than three billion doses in 2022. Messenger RNA genetic technology trains the body to reproduce spike proteins, similar to that found on the coronavirus. When exposed to the real virus later, the body recognizes the spike proteins and is able to fight them off.

Source: Manila Times May 10, 2021 09:00 UTC